mAbxience and Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
MADRID, Dec. 22, 2025 /PRNewswire/ — mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Amneal…
